Biomarkers for Prostate Cancer: PCA3, PHI, 4Kscore & More

Why are biomarkers needed? – Limitations of PSA

PSA screening reduces prostate cancer mortality but leads to overdiagnosis and unnecessary biopsies. PSA has limited specificity (30-40%) – most men with elevated PSA do NOT have cancer. Secondary biomarkers help:

• Reduce unnecessary biopsies (by 30-50%)
• Detect clinically significant (Gleason 7+) cancer
• Avoid overdiagnosis of low-risk (Gleason 6) cancer

PCA3 (Prostate Cancer Antigen 3) – urine-based

PCA3 is a non-coding RNA that is highly overexpressed in prostate cancer cells (100-1,000x) and not elevated in BPH or prostatitis.

Test details:

• Sample: First-catch urine after digital rectal exam (DRE)
• Result: PCA3 score (ratio of PCA3 to PSA mRNA)
• Cut-off: 25-35 (higher score = higher cancer risk)

Performance:

• Sensitivity: 50-60%
• Specificity: 70-80%
• AUC: 0.65-0.70
• Better than PSA alone for predicting biopsy outcome

Clinical utility:

• Men with prior negative biopsy and persistent elevated PSA
• Avoids 40-50% of unnecessary repeat biopsies

PHI (Prostate Health Index) – blood-based, FDA-approved

PHI combines total PSA, free PSA, and [-2]proPSA into a single score. It is FDA-approved for detecting prostate cancer in men with PSA 4-10 ng/mL.

Formula:

• PHI = ([-2]proPSA / free PSA) × √(total PSA)

Interpretation:

• PHI <25: Low risk (2-10% chance of cancer)
• PHI 25-35: Moderate risk (10-20% chance)
• PHI 35-55: High risk (20-40% chance)
• PHI >55: Very high risk (>50% chance)

Performance:

• AUC: 0.70-0.75 (better than total PSA or free PSA alone)
• Reduces unnecessary biopsies by 30-40%

Clinical utility:

• Men with PSA 4-10 ng/mL and normal DRE
• Helps decide whether to proceed with prostate biopsy

4Kscore – blood-based, predicts aggressive cancer

The 4Kscore combines total PSA, free PSA, intact PSA, and human kallikrein-2 (hK2) with clinical factors (age, DRE, prior biopsy). It predicts the risk of high-grade (Gleason 7+) prostate cancer.

Interpretation:

• Risk of Gleason 7+ cancer (percentage)
• Example: 4Kscore = 15% (15% chance of finding high-grade cancer on biopsy)

Performance:

• AUC: 0.75-0.80 for high-grade cancer
• Reduces unnecessary biopsies by 30-50%

Clinical utility:

• Men with elevated PSA (2-10 ng/mL) considering biopsy
• May identify men who can safely avoid biopsy (low 4Kscore)

SelectMDx – urine-based mRNA test

SelectMDx measures the expression of two mRNA biomarkers (HOXC6 and DLX1) in urine after DRE. It predicts the risk of high-grade (Gleason 7+) prostate cancer.

Performance:

• Sensitivity: 80-90%
• Negative predictive value: >90% (if low risk, very low chance of high-grade cancer)
• Reduces unnecessary biopsies by 40-50%

Clinical utility:

• Men with elevated PSA (2-10 ng/mL) considering first biopsy
• Negative SelectMDx (low risk) can safely avoid biopsy

ExoDx Prostate (IntelliScore) – exosome-based urine test

ExoDx Prostate (IntelliScore) measures three exosomal RNA biomarkers (ERG, PCA3, SPDEF) in urine without requiring DRE.

Advantages:

• No DRE required (patient collects urine at home or clinic)
• Predicts risk of high-grade (Gleason 7+) prostate cancer

Performance:

• AUC: 0.70-0.75
• Reduces unnecessary biopsies by 30-40%

Clinical utility:

• Men with PSA 2-10 ng/mL considering first biopsy
• May be used when DRE is not performed or declined

MiPS (Michigan Prostate Score) – combines PCA3 and T2:ERG

MiPS combines PCA3 and TMPRSS2-ERG fusion gene detection (if present) in urine after DRE. It provides a risk score for high-grade prostate cancer.

Performance:

• AUC: 0.75-0.80
• Better than PCA3 alone

Clinical utility:

• Men with elevated PSA considering biopsy
• Available at University of Michigan; not widely available

Clinical utility – reducing unnecessary biopsies

How biomarkers fit into clinical practice (NCCN guidelines):

• Step 1: PSA screening (age 45-50)
• Step 2: If PSA elevated (3-10 ng/mL), consider secondary biomarker (PHI, 4Kscore, SelectMDx, ExoDx, or PCA3)
• Step 3: If biomarker indicates low risk (PHI <25, 4Kscore <10%), consider deferring biopsy and repeat PSA in 6-12 months
• Step 4: If biomarker indicates high risk (PHI >35, 4Kscore >15%), proceed with MRI and/or biopsy

Biomarker comparison table:

Biomarker	Sample	FDA Approved	Medicare Coverage	Predicts High-Grade Cancer	DRE Required
PCA3	Urine	✓	✓	No	✓
PHI	Blood	✓	✓	No	No
4Kscore	Blood	✗	✓	Yes	No
SelectMDx	Urine	✗	✓	Yes	✓
ExoDx	Urine	✓	✓	Yes	No

Interactive FAQ – Prostate cancer biomarkers

---

Disclaimer: This information is for educational purposes and intended for clinicians and researchers. Biomarker selection should be individualised.